Laboratory Corporation of America Holdings (NYSE:LH)‘s stock had its “hold” rating reiterated by Robert W. Baird in a research report issued on Sunday.

LH has been the topic of several other research reports. ValuEngine lowered Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research report on Saturday, June 3rd. Barclays PLC lifted their price target on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. BidaskClub raised Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Credit Suisse Group reissued a “buy” rating and issued a $146.00 target price on shares of Laboratory Corporation of America Holdings in a report on Sunday, May 28th. Finally, Zacks Investment Research raised Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Laboratory Corporation of America Holdings presently has a consensus rating of “Buy” and a consensus price target of $164.00.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at 153.60 on Friday. The stock has a 50 day moving average price of $156.60 and a 200 day moving average price of $147.65. Laboratory Corporation of America Holdings has a 12 month low of $119.51 and a 12 month high of $164.22. The stock has a market cap of $15.64 billion, a P/E ratio of 21.51 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The firm’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.36 earnings per share. Equities analysts anticipate that Laboratory Corporation of America Holdings will post $9.54 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Laboratory Corporation of America Holdings (LH) Stock Rating Reaffirmed by Robert W. Baird” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/17/laboratory-corporation-of-america-holdings-lh-stock-rating-reaffirmed-by-robert-w-baird.html.

In related news, CEO David P. King sold 132,713 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total value of $20,843,903.78. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director R Sanders Williams sold 3,100 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $156.88, for a total value of $486,328.00. Following the completion of the sale, the director now owns 10,073 shares in the company, valued at $1,580,252.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 222,968 shares of company stock worth $34,980,922. Company insiders own 0.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Burgundy Asset Management Ltd. boosted its stake in shares of Laboratory Corporation of America Holdings by 2.3% in the second quarter. Burgundy Asset Management Ltd. now owns 74,216 shares of the medical research company’s stock valued at $11,440,000 after buying an additional 1,653 shares in the last quarter. Sentry Investment Management LLC boosted its stake in shares of Laboratory Corporation of America Holdings by 1.0% in the second quarter. Sentry Investment Management LLC now owns 7,756 shares of the medical research company’s stock valued at $1,196,000 after buying an additional 78 shares in the last quarter. Toronto Dominion Bank boosted its stake in shares of Laboratory Corporation of America Holdings by 25.5% in the second quarter. Toronto Dominion Bank now owns 34,655 shares of the medical research company’s stock valued at $5,342,000 after buying an additional 7,042 shares in the last quarter. Advisory Services Network LLC boosted its stake in shares of Laboratory Corporation of America Holdings by 7.4% in the second quarter. Advisory Services Network LLC now owns 12,213 shares of the medical research company’s stock valued at $1,883,000 after buying an additional 838 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Laboratory Corporation of America Holdings in the second quarter valued at approximately $700,000. Hedge funds and other institutional investors own 93.21% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.